CIK 0001815442
- Large accelerated filer
Kymera Therapeutics, Inc.
Sign in to watch- Ticker
- KYMR
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 812992166
- Phone
- +1 857-285-5314
- Business address
- 500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN, MA, 02472
- Former names
- Kymera Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $4,158,214
- in 2 filings, $3.4M under 10b5-1 plans
Net −$4,158,214. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 68 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-02-09 | Gollob Jared Chief Medical Officer | Sale 10b5-1 | −7,398 | $36.09 | $267K | 74,709 |
| 2024-02-09 | Gollob Jared Chief Medical Officer | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −46,137 | 62,883 | ||
| 2024-01-23 | Albers Jeffrey W. Director | Exercise or conversion 10b5-1 | +10,000 | $10.34 | $103K | 10,000 |
| 2024-01-23 | Albers Jeffrey W. Director | Sale 10b5-1 | −10,000 | $30.05 | $300K | 0 |
| 2024-01-23 | Albers Jeffrey W. Director | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −10,000 | 21,349 | ||
| 2024-01-05 | BVF PARTNERS L P/IL Director | Purchase · Pre-Funded Warrants to Purchase Common Stock | +550,425 | $25.25 | $13.9M | 550,425 |
| 2024-01-05 | BVF PARTNERS L P/IL Director | Purchase · Pre-Funded Warrants to Purchase Common Stock | +375,856 | $25.25 | $9.5M | 375,856 |
| 2024-01-05 | BVF PARTNERS L P/IL Director | Purchase · Pre-Funded Warrants to Purchase Common Stock | +52,733 | $25.25 | $1.3M | 52,733 |
| 2024-01-04 | Chiniara Ellen Chief Legal Officer | Sale | −3,295 | $22.58 | $74K | 34,205 |
| 2024-01-02 | Mainolfi Nello Chief Executive Officer | Exercise or conversion | +9,000 | $2.08 | $19K | 615,570 |
| 2024-01-02 | Mainolfi Nello Chief Executive Officer | Exercise or conversion · Stock Option (Right to Buy) | −9,000 | 519,972 | ||
| 2023-11-03 | Mainolfi Nello Chief Executive Officer | Exercise or conversion | +2,368 | $2.08 | $5K | 588,938 |
| 2023-11-03 | Mainolfi Nello Chief Executive Officer | Exercise or conversion | +17,632 | $2.08 | $37K | 606,570 |
| 2023-11-03 | Mainolfi Nello Chief Executive Officer | Exercise or conversion · Stock Option (Right to Buy) | −2,368 | 0 | ||
| 2023-11-03 | Mainolfi Nello Chief Executive Officer | Exercise or conversion · Stock Option (Right to Buy) | −17,632 | 528,972 | ||
| 2023-11-03 | BVF PARTNERS L P/IL Director | Purchase | +103,885 | $14.07 | $1.5M | 2,656,191 |
| 2023-11-03 | BVF PARTNERS L P/IL Director | Purchase | +83,708 | $14.07 | $1.2M | 2,104,075 |
| 2023-11-03 | BVF PARTNERS L P/IL Director | Purchase | +10,106 | $14.07 | $142K | 294,632 |
| 2023-11-02 | BVF PARTNERS L P/IL Director | Purchase | +57,618 | $11.64 | $671K | 2,552,306 |
| 2023-11-02 | BVF PARTNERS L P/IL Director | Purchase | +132,016 | $11.64 | $1.5M | 2,020,367 |
Page 31 of 41 · 810 trades